Rats with lesions in the neostriatal region that belongs to the prefrontal system were trained in two versions of delayed alternation. They performed as proficiently as intact animals in a two-key operant chamber. The same operated rats took many more trials to reach criterion when subsequently compared with the same control group in a T-maze. This finding demonstrates that variants of delayed alternation are not equivalent for animals with lesions in the prefrontal system. Observations suggested that delayed alternation in the operant chamber may be mastered by positional mediation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Central venous pressure as a method of optimising atrio-ventricular delay after cardiac surgery.
PLoS One
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Introduction: Haemodynamic atrioventricular delay (AVD) optimisation has primarily focussed on signals that are not easy to acquire from a pacing system itself, such as invasive left ventricular catheterisation or arterial blood pressure (ABP). In this study, standard clinical central venous pressure (CVP) signals are tested as a potential alternative.
Methods: Sixteen patients with a temporary pacemaker after cardiac surgery were studied.
Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning.
Mol Ther Oncol
September 2024
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Hematopoietic stem cell transplantation (HSCT) is widely used to treat patients with life-threatening hematologic and immune system disorders. Current nontargeted chemo-/radiotherapy conditioning regimens cause tissue injury and induce an array of immediate and delayed adverse effects, limiting the application of this life-saving treatment. The growing demand to replace canonical conditioning regimens has led to the development of alternative approaches, such as antibody-drug conjugates, naked antibodies, and CAR T cells.
View Article and Find Full Text PDFUnderstanding Cancer Treatment Decision Making Among Cancer Survivors: Weighing Cancer Recurrence Versus Cardiotoxicity.
Psychooncology
January 2025
Integrative Biological and Behavioral Sciences, Division of Extramural Scientific Programs, National Institute on Minority Health and Health Disparities, Rockville, Maryland, USA.
Background: Nearly 20% of US cancer survivors develop cardiovascular disease (CVD) from cardiotoxic cancer treatments. Patients and providers may consider alternative treatments to lower cardiotoxicity risk, but these may be less effective at preventing relapse/recurrence, presenting a difficult tradeoff.
Aims: This study explored survivors' cancer treatment decision-making when weighing this tradeoff.
Recurrent peripheral intravenous catheterization in neonates: A case series.
Nurs Crit Care
January 2025
Women's and Newborns Service, Grantley Stable Neonatal Unit, Nursing and Midwifery Research Centre; Royal Brisbane and Women's Hospital, Herston, Australia.
Neonatal peripheral intravenous catheters (PIVCs) can be difficult to insert, often requiring multiple attempts, with each attempt causing pain and delaying treatment. The aim of this study was describe the clinical characteristics of neonates requiring multiple PIVCs during hospitalization. A secondary case series of neonates requiring three or more PIVCs during their admission were identified from a cohort admitted to an Australian Neonatal Unit between October 2020 and February 2021.
View Article and Find Full Text PDFNovel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency.
PLoS One
January 2025
The National Centre of Vaccines and Bioprocessing, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Methotrexate (MTX) is classified as an antimetabolite. It's commonly used to treat lung cancer. MTX is an immunosuppressant following the above-mentioned mechanism of action due to its poor selectivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!